RESUMO
PURPOSE: Physical activity research among patients with metastatic breast cancer (MBC) is limited. This study examined the feasibility and potential benefits of Fit2ThriveMB, a tailored mHealth intervention. METHODS: Insufficiently active individuals with MBC (n = 49) were randomized 1:1 to Fit2ThriveMB (Fit2ThriveMB app, Fitbit, and weekly coaching calls) or Healthy Lifestyle attention control (Cancer.Net app and weekly calls) for 12 weeks. Fit2ThriveMB aimed to increase daily steps via an algorithm tailored to daily symptom rating and step goal attainment. The primary outcome was feasibility defined as ≥ 80% completion rate. Secondary feasibility metrics included meeting daily step goal and wearing the Fitbit ≥ 70% of study days, fidelity, adherence to intervention features and safety. Secondary outcomes included physical activity, sedentary time, patient reported outcomes (PROs), health-related quality of life (QOL) and social cognitive theory constructs. A subsample (n = 25) completed functional performance tests via video conferencing. RESULTS: The completion rate was 98% (n = 1 died). No related adverse events were reported. Fit2ThriveMB participants (n = 24) wore the Fitbit 92.7%, met their step goal 53.1%, set a step goal 84.6% and used the app 94.1% of 84 study days. Intent-to-treat analyses indicated trends toward improvements in activity, QOL, and some PROs, social cognitive theory constructs, and functional performance tests favoring the Fit2ThriveMB group. Significant effects favoring Fit2ThriveMB were observed for self-efficacy and goal-setting. However, some PROs and functional performance improvements favored the control group (p-values > 0.05). CONCLUSIONS: Fit2ThriveMB is feasible and safe for patients with MBC and warrants further evaluation in randomized controlled trials with larger sample sizes. Registration Clinicaltrials.gov NCT04129346, https://clinicaltrials.gov/ct2/show/NCT04129346.
Assuntos
Neoplasias da Mama , Exercício Físico , Estudos de Viabilidade , Medidas de Resultados Relatados pelo Paciente , Qualidade de Vida , Humanos , Feminino , Neoplasias da Mama/patologia , Neoplasias da Mama/psicologia , Neoplasias da Mama/terapia , Pessoa de Meia-Idade , Telemedicina , Idoso , Promoção da Saúde/métodos , Adulto , Metástase Neoplásica , Projetos Piloto , Aplicativos MóveisRESUMO
PURPOSE: The purpose of this study was to gain an understanding of older gynecologic cancer patients' preferences and opinions related to physical activity during chemotherapy, including interventions to promote physical activity. METHODS: Gynecologic cancer patients 60 years or older receiving chemotherapy at a single institution within the last 12 months completed questionnaires and a semi-structured interview asking about their preferences for physical activity interventions aimed at promoting physical activity while receiving treatment. RESULTS: Among the 30 gynecologic cancer patients surveyed and interviewed, a majority agreed with the potential usefulness of a physical activity intervention during chemotherapy (67%) and most reported they would be willing to use an activity tracker during chemotherapy (73%). They expressed a preference for an aerobic activity intervention such as walking, indicated a desire for education from their clinical team on the effects physical activity can have on treatment symptoms, and stated a need for an intervention that could be accessed from anywhere and anytime. Additionally, they emphasized a need for an intervention that considered their treatment symptoms as these were a significant barrier to physical activity while on chemotherapy. CONCLUSION: In this study of older gynecologic cancer patients receiving chemotherapy, most were open to participating in a virtually accessible and symptom-tailored physical activity intervention to promote physical activity during chemotherapy.
Assuntos
Exercício Físico , Neoplasias dos Genitais Femininos , Humanos , Feminino , Idoso , Caminhada , Inquéritos e Questionários , Neoplasias dos Genitais Femininos/tratamento farmacológicoRESUMO
Clinical genome and exome sequencing (CGES) may identify variants leading to targeted management of existing conditions. Yet, CGES often fails to identify pathogenic diagnostic variants and introduces uncertainties by detecting variants of uncertain significance (VUS) and secondary findings. This study investigated how families understand findings and adjust their perspectives on CGES. As part of NIH's Clinical Sequencing Exploratory Research Consortium, children were recruited from clinics at the Children's Hospital of Pennsylvania (CHOP) and offered exome sequencing. Primary pathogenic and possibly pathogenic, and some secondary findings were returned. Investigators digitally recorded results disclosure sessions and conducted 3-month follow up interviews with 10 adolescents and a parent. An interdisciplinary team coded all transcripts. Participants were initially disappointed with findings, yet reactions evolved within disclosure sessions and at 3-month interviews toward acceptance and satisfaction. Families erroneously expected, and prepared extensively, to learn about risk for common conditions. During disclosure sessions, parents and adolescents varied in how they monitored and responded to each others reactions. Several misinterpreted, or overestimated, the utility of findings to attribute meaning and achieve closure for the CGES experience. Participants perceived testing as an opportunity to improve disease management despite results that did not introduce new treatments or diagnoses. Future research may examine whether families experience cognitive dissonance regarding discrepancies between expectations and findings, and how protective buffering minimizes the burden of disappointment on loved ones. As CGES is increasingly integrated into clinical care providers must contend with tempering family expectations and interpretations of findings while managing complex medical care.
Assuntos
Dissonância Cognitiva , Sequenciamento do Exoma , Pais/psicologia , Adaptação Psicológica , Adolescente , Adulto , Criança , Revelação , Medo , Feminino , Frustração , Aconselhamento Genético , Testes Genéticos , Genoma Humano , Humanos , Masculino , Pessoa de Meia-Idade , Motivação , Inquéritos e Questionários , Incerteza , Adulto JovemRESUMO
Deleterious mutations in BRCA1 or BRCA2 genes increase a woman's lifetime risk of breast and ovarian cancer. Risk management guidelines endorse early detection and prevention behaviors. Despite expressed intent, uptake of these measures remains low. This longitudinal, qualitative study integrated retrospective and prospective data to distinguish factors shaping intent to act from those that are catalysts to taking action to reduce cancer risk. Twelve BRCA1/2 mutation-positive women participating in the National Cancer Institute's Breast Imaging Study aged 18-35 completed two semi-structured interviews three years apart. Researchers completed focused coding to identify points of behavioral intent and action and contextual factors acting as catalysts upon participant narratives. All women shared only two action steps: seeking information about cancer risk and completing genetic testing. The constellation of action steps created a unique action trajectory that was defined, with precise ideas about risk perception and clear behavioral response, or iterative, in which unanticipated life events shifted the speed, accessibility, or order in which risk management and family planning goals were prioritized, planned, or executed. Factors shifting action steps included salient, unanticipated life events, such as infertility, insurance/financial constraints, birth of the last child, or a relative's cancer diagnosis. Focus on cancer morbidity may obfuscate how women prioritize actions, and ignore varied pragmatic, relational, and social factors affecting how intended actions are completed, particularly during the reproductive years. We recommend providers update patients' risk management plans at each visit to assess readiness for next steps and reduce reluctance to discuss, or guilt associated with, change.
Assuntos
Neoplasias da Mama/prevenção & controle , Genes BRCA1 , Genes BRCA2 , Mutação , Neoplasias Ovarianas/prevenção & controle , Adolescente , Adulto , Neoplasias da Mama/genética , Feminino , Testes Genéticos , Humanos , Estudos Longitudinais , Neoplasias Ovarianas/genética , Estudos Prospectivos , Pesquisa Qualitativa , Estudos Retrospectivos , Comportamento de Redução do Risco , Adulto JovemAssuntos
Infecções Oculares Parasitárias/diagnóstico , Miíase/diagnóstico , Doenças Retinianas/diagnóstico , Epitélio Pigmentado da Retina/parasitologia , Transtornos da Visão/diagnóstico , Infecções Oculares Parasitárias/parasitologia , Infecções Oculares Parasitárias/fisiopatologia , Feminino , Angiofluoresceinografia , Humanos , Pessoa de Meia-Idade , Miíase/parasitologia , Miíase/fisiopatologia , Miopia Degenerativa , Doenças Retinianas/parasitologia , Doenças Retinianas/fisiopatologia , Epitélio Pigmentado da Retina/fisiopatologia , Tomografia de Coerência Óptica , Transtornos da Visão/parasitologia , Transtornos da Visão/fisiopatologia , Acuidade Visual/fisiologia , Vitrectomia , Hemorragia Vítrea/cirurgiaRESUMO
PURPOSE: To describe a case of postoperative retinal toxicity following the use of mitomycin C during a routine trabeculectomy. METHODS: Case report of a single patient who underwent complete ophthalmic examination and multimodal imaging, including color fundus photos, optical coherence tomography, fundus autofluorescence, and fluorescein angiography. The study was declared exempt by the Institutional Review Board of Northwestern University. This research followed the tenets of the Declaration of Helsinki. RESULTS: The patient developed profound vision loss and retinal damage during the postoperative course. Posterior segment findings include loss of vascular perfusion, diffuse loss of the outer, then inner, retinal layers, and subsequent total retinal detachment. CONCLUSION: Although mitomycin C is commonly used in glaucoma filtering surgeries, reports of postoperative posterior segment toxicity are rare. The etiology of postoperative toxicity in this case is probable inadvertent intraocular injection of mitomycin C.
Assuntos
Glaucoma , Trabeculectomia , Humanos , Mitomicina , Glaucoma/cirurgia , Retina , Injeções Intraoculares , Pressão IntraocularRESUMO
BACKGROUND: Epicardial adipose tissue (EAT) volume is a marker of visceral obesity that can be measured in coronary computed tomography angiograms (CCTA). The clinical value of integrating this measurement in routine CCTA interpretation has not been documented. OBJECTIVES: This study sought to develop a deep-learning network for automated quantification of EAT volume from CCTA, test it in patients who are technically challenging, and validate its prognostic value in routine clinical care. METHODS: The deep-learning network was trained and validated to autosegment EAT volume in 3,720 CCTA scans from the ORFAN (Oxford Risk Factors and Noninvasive Imaging Study) cohort. The model was tested in patients with challenging anatomy and scan artifacts and applied to a longitudinal cohort of 253 patients post-cardiac surgery and 1,558 patients from the SCOT-HEART (Scottish Computed Tomography of the Heart) Trial, to investigate its prognostic value. RESULTS: External validation of the deep-learning network yielded a concordance correlation coefficient of 0.970 for machine vs human. EAT volume was associated with coronary artery disease (odds ratio [OR] per SD increase in EAT volume: 1.13 [95% CI: 1.04-1.30]; P = 0.01), and atrial fibrillation (OR: 1.25 [95% CI: 1.08-1.40]; P = 0.03), after correction for risk factors (including body mass index). EAT volume predicted all-cause mortality (HR per SD: 1.28 [95% CI: 1.10-1.37]; P = 0.02), myocardial infarction (HR: 1.26 [95% CI:1.09-1.38]; P = 0.001), and stroke (HR: 1.20 [95% CI: 1.09-1.38]; P = 0.02) independently of risk factors in SCOT-HEART (5-year follow-up). It also predicted in-hospital (HR: 2.67 [95% CI: 1.26-3.73]; P ≤ 0.01) and long-term post-cardiac surgery atrial fibrillation (7-year follow-up; HR: 2.14 [95% CI: 1.19-2.97]; P ≤ 0.01). CONCLUSIONS: Automated assessment of EAT volume is possible in CCTA, including in patients who are technically challenging; it forms a powerful marker of metabolically unhealthy visceral obesity, which could be used for cardiovascular risk stratification.
Assuntos
Fibrilação Atrial , Doenças Cardiovasculares , Doença da Artéria Coronariana , Aprendizado Profundo , Humanos , Obesidade Abdominal , Fatores de Risco , Valor Preditivo dos Testes , Doença da Artéria Coronariana/diagnóstico por imagem , Tomografia Computadorizada por Raios X , Pericárdio/diagnóstico por imagem , Fatores de Risco de Doenças Cardíacas , Tecido Adiposo/diagnóstico por imagem , Medição de RiscoRESUMO
The association of cargoes to kinesins is thought to promote kinesin activation, yet the validation of such a model with native cargoes is lacking because none is known to activate kinesins directly in an in vitro system of purified components. The RAN-binding protein 2 (RANBP2), through its kinesin-binding domain (KBD), associates in vivo with kinesin-1, KIF5B/KIF5C. Here, we show that KBD and its flanking domains, RAN GTPase-binding domains 2 and 3 (RBD2/RBD3), activate the ATPase activity of KIF5B approximately 30-fold in the presence of microtubules and ATP. The activation kinetics of KIF5B by RANBP2 is biphasic and highly cooperative. Deletion of one of its RBDs lowers the activation of KIF5B threefold and abolishes cooperativity. Remarkably, RBD2-KBD-RBD3 induces unfolding and modest activation of KIF5B in the absence of microtubules. Hence, RANBP2 is the first native and positive allosteric activator known to jump-start and boost directly the activity of a kinesin.
Assuntos
Regulação Alostérica/fisiologia , Sistema Livre de Células/metabolismo , Cinesinas/metabolismo , Chaperonas Moleculares/metabolismo , Complexo de Proteínas Formadoras de Poros Nucleares/metabolismo , Adenosina Trifosfatases/metabolismo , Humanos , Cinesinas/química , Cinesinas/genética , Cinética , Microtúbulos/metabolismo , Modelos Biológicos , Chaperonas Moleculares/química , Chaperonas Moleculares/genética , Complexo de Proteínas Formadoras de Poros Nucleares/química , Complexo de Proteínas Formadoras de Poros Nucleares/genética , Ligação Proteica , Estrutura Terciária de ProteínaRESUMO
PURPOSE: To report OCTA findings in 3 cases, 2 active and 1 inactive, of serpiginous choroidopathy (SC) and describe OCTA changes in response to treatment. DESIGN: Retrospective case series. PARTICIPANTS: We studied 6 eyes of 3 patients with SC. METHODS: Retrospective case series of 3 patients with SC undergoing multimodal imaging, including OCTA. In 1 treated eye, both pre- and posttreatment images were compared. MAIN OUTCOME MEASURES: Description of OCTA findings in patients with SC. RESULTS: In the active phase, OCTA images show an apparent absence of the choriocapillaris with variable outer retinal and retinal pigment epithelial thickening. After treatment, OCTA of previously active lesions demonstrates a partial reappearance of the choriocapillaris, especially at lesion margins. In inactive SC, the choriocapillaris, along with the retinal pigment epithelium and outer retina, is notably absent. CONCLUSIONS: Optical coherence tomography angiography suggests absence of choriocapillaris in both active and inactive phases of SC with partial reestablishment following treatment. Although the exact pathogenesis of SC is not elucidated by these findings, OCTA images allow us to better evaluate choroidal involvement.
RESUMO
Optical coherence tomographic angiography (OCTA) is emerging as a rapid, noninvasive imaging modality that can provide detailed structural and flow information on retinal and choroidal vasculature. This review contains an introduction of OCTA and summarizes the studies to date on OCTA imaging in age-related macular degeneration.